27F Stock Chart & Stats
€0.47
€0.02(0.21%)
At close: 4:00 PM EST
€0.47
€0.02(0.21%)
Day’s Range― - ―
52-Week Range€3.40 - €849.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)72.00
Market Cap
€10.75M
Enterprise Value€94.00
Total Cash (Recent Filing)€8.76M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding19,339,787
10 Day Avg. Volume0
30 Day Avg. Volume72
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Leverage Materially Reduced (debt = 0)Elimination of total debt materially lowers fixed interest obligations and default risk, improving financial flexibility. Over a multi-month horizon this reduces near-term liquidity strain and cost structure volatility, extending runway options and making equity or non-debt fundraising less punitive.
Positive And Increasing Shareholders' EquityAn increase in shareholders' equity provides a larger residual cushion for creditors and shows net asset improvement. Structurally, positive equity supports the firm's ability to raise additional capital, absorb future losses, and negotiate partnerships or licensing without immediate solvency concerns.
Demonstrated Access To Public Capital MarketsFiling a prospectus supplement under an existing shelf indicates operational readiness to issue securities and legally access public funding. Over the coming months this structural ability is critical for clinical-stage biotech to finance R&D and trials without depending solely on private placements.
Bears Say
Zero Reported RevenueA sustained zero revenue base means the company cannot fund operations from product sales and remains fully dependent on external capital. Structurally this limits self-sustainability, increases financing frequency risk, and places long-term viability on successful clinical outcomes or licensing deals.
Persistent Heavy Cash BurnConsistent negative operating and free cash flow accelerates the need for dilutive capital raises and shortens runway. Over a medium-term horizon this creates funding overhang, constrains R&D sequencing, and forces prioritization that can delay programs or reduce optionality for strategic partnerships.
Very Limited Operating Capacity (small Workforce)A headcount of six suggests constrained internal capability to run multiple clinical, regulatory, or commercialization initiatives simultaneously. Structurally this raises execution risk, increases dependency on external partners or CROs, and can lengthen timelines and raise outsourced costs over months.
27F FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was €3.40 and its highest was €849.50 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is €10.75M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Aug 06, 2026 which is in 9 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on May 19, 2026. The company reported -€0.119 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 19,339,787 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -€0.119 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in DE:27F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.